Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Translating Molecular Pathology Into a Therapeutic Strategy in SCA38, a Newly Identified Form of Spinocerebellar Ataxia

NCT03109626 is registered in ClinicalTrials.gov with Barbara Borroni as lead sponsor.

NCT NCT03109626
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03109626 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Translating Molecular Pathology Into a Therapeutic Strategy in SCA38, a Newly Identified Form of Spinocerebellar Ataxia
Lead sponsor
Barbara Borroni
Phase
Not applicable
Overall status
Completed
Start date
June 17, 2015
Completion date
June 25, 2018
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sca38